Sarepta discontinues work on next-gen exon-skipping drug for Duchenne

Sarepta Therapeutics is stopping development of vesleteplirsen, an experimental exon 51-skipping therapy for Duchenne muscular dystrophy patients with certain mutations. It's also halting work on all programs that use the same peptide, R&D head Louise ...